Analysts’ Weekly Ratings Changes for 4D Molecular Therapeutics (FDMT)

A number of firms have modified their ratings and price targets on shares of 4D Molecular Therapeutics (NASDAQ: FDMT) recently:

• 9/19/2024 – 4D Molecular Therapeutics had its “outperform” rating reaffirmed by analysts at Leerink Partners. They now have a $36.00 price target on the stock, down previously from $40.00.
• 9/19/2024 – 4D Molecular Therapeutics had its price target raised by analysts at Chardan Capital from $38.00 to $39.00. They now have a “buy” rating on the stock.
• 9/19/2024 – 4D Molecular Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
• 9/9/2024 – 4D Molecular Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 8/9/2024 – 4D Molecular Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
• 7/22/2024 – 4D Molecular Therapeutics had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $40.00 price target on the stock.

4D Molecular Therapeutics Trading Down 11.9 %

FDMT traded down $1.60 during mid-day trading on Friday, hitting $11.90. 2,125,071 shares of the stock were exchanged, compared to its average volume of 890,993. The firm’s fifty day moving average is $16.12 and its two-hundred day moving average is $22.59. 4D Molecular Therapeutics, Inc. has a 1-year low of $9.44 and a 1-year high of $36.25. The company has a market cap of $615.27 million, a PE ratio of -4.88 and a beta of 2.80.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.09. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $1.90 million. As a group, research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.75 earnings per share for the current year.

Insider Transactions at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, CEO David Kirn sold 12,930 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $23.10, for a total value of $298,683.00. Following the sale, the chief executive officer now owns 1,059,153 shares of the company’s stock, valued at approximately $24,466,434.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other 4D Molecular Therapeutics news, CEO David Kirn sold 12,930 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $23.10, for a total value of $298,683.00. Following the sale, the chief executive officer now directly owns 1,059,153 shares of the company’s stock, valued at approximately $24,466,434.30. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Scott Bizily sold 4,248 shares of 4D Molecular Therapeutics stock in a transaction on Monday, July 1st. The stock was sold at an average price of $21.36, for a total transaction of $90,737.28. Following the sale, the insider now directly owns 1,737 shares of the company’s stock, valued at $37,102.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,347 shares of company stock valued at $785,566. 7.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several large investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC grew its position in shares of 4D Molecular Therapeutics by 702.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after acquiring an additional 3,026 shares during the last quarter. Quest Partners LLC grew its position in 4D Molecular Therapeutics by 17,409.1% during the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock worth $121,000 after purchasing an additional 5,745 shares during the last quarter. Entropy Technologies LP acquired a new position in 4D Molecular Therapeutics in the first quarter valued at $239,000. China Universal Asset Management Co. Ltd. increased its stake in 4D Molecular Therapeutics by 93.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,579 shares of the company’s stock valued at $305,000 after purchasing an additional 4,628 shares during the period. Finally, ProShare Advisors LLC purchased a new stake in shares of 4D Molecular Therapeutics in the first quarter valued at about $344,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.